Cowen & Co. analyst Yaron Werber maintained a Buy rating on Amgen Inc (AMGN) today and set a price target of $229. The company’s shares closed yesterday at $169.69, close to its 52-week low of $166.30.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 12.8% and a 60.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.
Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $210.30, implying a 23.9% upside from current levels. In a report issued on May 10, Mizuho Securities also maintained a Buy rating on the stock with a $208 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $210.19 and a one-year low of $166.30. Currently, Amgen Inc has an average volume of 2.87M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
